VRB-101
(Oral)
(Oral)
Transforming lives by accelerating innovation in cardiometabolic health
About
Obesity and its associated complications comprise some of the world’s most pressing health issues.
We created Verdiva Bio to accelerate the development of differentiated medicines that address the significant unmet medical needs in this space.
Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options.
The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options to transform the lives of millions.
Verdiva’s most advanced therapy in development is VRB-101, an oral GLP-1 peptide that has demonstrated compelling efficacy potential in a phase 1 study, which also confirmed the viability of once-weekly dosing.
The company’s portfolio includes multiple amylin molecules (oral and subcutaneous agonists) and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss.
Pipeline
Potential best-in-class therapies for cardiometabolic conditions
Program
MoA
Dosing
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
GLP-1
Once-weekly peptide
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
VRB-103
(Oral)
(Oral)
Amylin (DACRA)
Once-weekly peptide
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
VRB-103 + VRB-101
(Oral)
(Oral)
Amylin + GLP-1
Once-weekly or daily
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
VRB-102 + VRB-101
(Injectable)
(Injectable)
Amylin* + GLP-1
Once-weekly peptide(s)
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
*Dual amylin and calcitonin receptor against (DACRA) agent
Team
Leadership
Board
Leadership
Board
Investors
Contact
Do you have questions or want to learn more about our transformative work?
Reach out to us using the form here. We value your input and are excited to engage with like-minded individuals, potential partners, and collaborators who share our passion for innovation in metabolic disease research.
